Loading…
Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy
A lack of the T cell-inflamed tumor microenvironment limits the efficacy of immune checkpoint inhibitors (ICIs). Activation of stimulator of interferon genes (STING)-mediated innate immunity has emerged as a novel therapeutic approach in cancer therapy. 2',3'-Cyclic GMP-AMP (cGAMP) is a na...
Saved in:
Published in: | Journal of medicinal chemistry 2023-11, Vol.66 (22), p.15141-15170 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | A lack of the T cell-inflamed tumor microenvironment limits the efficacy of immune checkpoint inhibitors (ICIs). Activation of stimulator of interferon genes (STING)-mediated innate immunity has emerged as a novel therapeutic approach in cancer therapy. 2',3'-Cyclic GMP-AMP (cGAMP) is a natural STING agonist; however, cGAMP is subjected to endogenous degradation by ecto-nucleotide pyrophosphatase phosphodiesterase 1 (ENPP1). To improve the ICI response rate, we developed
, a novel ENPP1 inhibitor with phthalazin-1(2
)-one as the core scaffold.
inhibited the cGAMP hydrolysis by ENPP1 in vitro (IC
= 68 nM) and enhanced the STING-mediated type I interferon response in both immune and tumor cells.
demonstrated excellent metabolic stability and bioavailability (
= 65%). Orally administered
promoted tumor growth inhibition in a CT26 syngeneic model and increased the anti-PD-L1 response. Furthermore,
-induced immunological memory prevented the tumor relapse against tumor rechallenge, suggesting the promising therapeutic potential of
. |
---|---|
ISSN: | 0022-2623 1520-4804 |
DOI: | 10.1021/acs.jmedchem.3c01061 |